Dr. Robert Butz Named VP of Global Regulatory Affairs for MDS Pharma Services
18 Décembre 2003 - 9:00PM
PR Newswire (US)
Dr. Robert Butz Named VP of Global Regulatory Affairs for MDS
Pharma Services MONTREAL, Dec. 18 /PRNewswire-FirstCall/ -- MDS
Pharma Services, a leading provider of innovative drug discovery
and development solutions, has named Robert Butz, Ph.D., as vice
president, Global Regulatory Affairs. Based at the company's
offices in King of Prussia, Penn., Dr. Butz will have
responsibility for expanding and enhancing the company's global
regulatory affairs services. "Regulatory affairs is an area of key
strategic importance for us, based on our in-depth analysis of
where the market is headed," said Doug Squires, president and CEO.
"As drug development moves towards personalized medicine, and
medical device manufacturers increasingly combine their products
with a drug or biologic, more and more clients are turning to us
for our regulatory expertise. Biotechnology companies, in
particular, need significant support to navigate an unfamiliar
regulatory environment." Squires added that MDS Pharma Services'
renewed focus on regulatory affairs is also important to its Drug
Development Programs group, which now includes regulatory affairs
as part of its integrated services to biotechnology and
pharmaceutical clients worldwide. Drug Development Programs
incorporates a focused group of senior scientific consultants who
are responsible for driving implementation of each client's drug
development plan. Dr. Butz has nearly 30 years of management and
drug development experience, including regulatory affairs, in the
pharmaceutical, contract research and biotech industries. His
background includes leadership positions with Burroughs Wellcome
Co. and Quintiles, as well as the co-founding of several biotech
companies in recent years. He earned his doctorate in Physiology
and Pharmacology at Duke University. MDS Pharma Services offers a
full spectrum of resources to meet the drug discovery and
development needs of the pharmaceutical and biotechnology
industries. With numerous facilities strategically located around
the world, the company applies advanced scientific and
technological expertise to each stage of the drug discovery and
development process -- early stage: lead optimization, pre-IND
research, pharmaceutical and biopharmaceutical development, early
clinical research (bioequivalence, phases I-IIa) and bioanalysis;
and late stage: global clinical development (phases IIb-IV) and
central lab. For more information, visit MDS Pharma Services' Web
site at http://www.mdsps.com/ . MDS Pharma Services is part of MDS
Inc. (TSE:MDS)(NYSE:MDZ), an international health and life sciences
company. In many of its products and services, it is among the
largest and most respected companies in the world. MDS's focus is
on advancing health through science. It does this by providing:
laboratory testing, imaging agents for nuclear medicine testing,
sterilization systems for medical and consumer products, research
services to speed discovery and development of new drugs, therapy
systems for planning and delivery of cancer treatment, analytical
instruments to assist in the development of new drugs, and
medical/surgical supplies. MDS employs nearly 11,000 highly skilled
people at its global operations on five continents. Detailed
information about the company is available at the MDS Web site at
http://www.mdsintl.com/ or by calling 1-888-MDS-7222, 24 hours a
day. DATASOURCE: MDS Pharma Services CONTACT: Kevin Langin of MDS
Pharma Services, +1-402-476-2811 Web site: http://www.mdsintl.com/
http://www.mdsps.com/
Copyright
Mds (NYSE:MDZ)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Mds (NYSE:MDZ)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Mds (New York Stock Exchange): 0 recent articles
Plus d'articles sur Mds